JP2008044951A5 - - Google Patents

Download PDF

Info

Publication number
JP2008044951A5
JP2008044951A5 JP2007238844A JP2007238844A JP2008044951A5 JP 2008044951 A5 JP2008044951 A5 JP 2008044951A5 JP 2007238844 A JP2007238844 A JP 2007238844A JP 2007238844 A JP2007238844 A JP 2007238844A JP 2008044951 A5 JP2008044951 A5 JP 2008044951A5
Authority
JP
Japan
Prior art keywords
fentanyl
equivalent
administered
use according
nasal spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007238844A
Other languages
English (en)
Other versions
JP2008044951A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2008044951A publication Critical patent/JP2008044951A/ja
Publication of JP2008044951A5 publication Critical patent/JP2008044951A5/ja
Pending legal-status Critical Current

Links

Claims (20)

  1. ０.５〜２０ｍｇ／ｍｌのフェンタニルに等価な濃度範囲で、９５〜１００％の水を含む適当な溶媒中にクエン酸フェンタニルの溶液を含む医薬組成物を送達するための鼻スプレー。
  2. 濃度範囲が、０.６〜１５ｍｇ／ｍｌのフェンタニルに等価である請求項１に記載の鼻スプレー。
  3. 濃度範囲が、０.７５〜１０ｍｇ／ｍｌのフェンタニルに等価である請求項２に記載の鼻スプレー。
  4. 濃度が０．７５ｍｇ／ｍｌ，１ｍｇ／ｍｌ，１．５ｍｇ／ｍｌ、２ｍｇ／ｍｌ，４ｍｇ／ｍｌ，８ｍｇ／ｍｌ、または１０ｍｇ／ｍｌのフェンタニルに等価である請求項３に記載の鼻スプレー。
  5. 溶媒が等調性食塩水である請求項１〜４のいずれかに記載の鼻スプレー。
  6. 溶媒が更にポリエチレングリコールを含む請求項１〜５のいずれかに記載の鼻スプレー。
  7. 哺乳動物における痛みを治療、緩和または低減するための薬剤の製造のためのクエン酸フェンタニルの使用であって、該薬剤は、０.５〜２０ｍｇ／ｍｌのフェンタニルに等価な濃度範囲で、９５〜１００％の水を含む適当な溶媒中にクエン酸フェンタニルの溶液を含み、鼻スプレー手段により１回の投与で７０〜５００μｇのフェンタニルに等価の量で鼻腔内に投与されるものである、使用。
  8. ７５〜３００μｇのフェンタニルに等価の量が投与されるものである、請求項７に記載の使用。
  9. ７０μｇ，８０μｇ，９０μｇ，１００μｇ，１２５μｇ，１５０μｇ，２００μｇ，２５０μｇ，３００μｇ，３５０μｇ，４００μｇ，４５０μｇ，または５００μｇのフェンタニルに等価の量が投与されるものである、請求項７に記載の使用。
  10. ７５μｇのフェンタニルに等価の量が投与されるものである、請求項７に記載の使用。
  11. １００μｇのフェンタニルに等価の量が投与されるものである、請求項７に記載の使用。
  12. １５０μｇのフェンタニルに等価の量が投与されるものである、請求項７に記載の使用。
  13. ２００μｇのフェンタニルに等価の量が投与されるものである、請求項７に記載の使用。
  14. ４００μｇのフェンタニルに等価の量が投与されるものである、請求項７に記載の使用。
  15. 濃度が０．７５ｍｇ／ｍｌ，１ｍｇ／ｍｌ，１．５ｍｇ／ｍｌ、２ｍｇ／ｍｌ，４ｍｇ／ｍｌ，８ｍｇ／ｍｌ、または１０ｍｇ／ｍｌのフェンタニルに等価である請求項７〜１４のいずれかに記載の使用。
  16. 急性の痛みの治療、緩和または低減のためのものである請求項７〜１５のいずれかに記載の使用。
  17. ブレークスルー痛の治療、緩和または低減のためのものである請求項７〜１５のいずれかに記載の使用。
  18. 個体がさらに鎮痛薬を投与される、請求項７〜１７のいずれかに記載の使用。
  19. 鎮痛薬がフェンタニルまたはその塩である請求項１８に記載の使用。
  20. 哺乳動物における痛みを治療、緩和または低減するための薬剤の製造のためのクエン酸フェンタニルの使用であって、該薬剤は、０.５〜２０ｍｇ／ｍｌのフェンタニルに等価な濃度範囲で、９５〜１００％の水を含む適当な溶媒中にクエン酸フェンタニルの溶液を含み、１回の投与で７０〜５００μｇのフェンタニルに等価の量の鼻スプレー手段により鼻腔内投与のために供されるものである、使用。
JP2007238844A 2000-07-31 2007-09-14 鼻内投与用フェンタニル組成物 Pending JP2008044951A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200001154 2000-07-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2002515260A Division JP4898073B2 (ja) 2000-07-31 2001-07-31 鼻内投与用フェンタニル組成物

Publications (2)

Publication Number Publication Date
JP2008044951A JP2008044951A (ja) 2008-02-28
JP2008044951A5 true JP2008044951A5 (ja) 2010-06-03

Family

ID=8159630

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002515260A Expired - Lifetime JP4898073B2 (ja) 2000-07-31 2001-07-31 鼻内投与用フェンタニル組成物
JP2007238844A Pending JP2008044951A (ja) 2000-07-31 2007-09-14 鼻内投与用フェンタニル組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2002515260A Expired - Lifetime JP4898073B2 (ja) 2000-07-31 2001-07-31 鼻内投与用フェンタニル組成物

Country Status (24)

Country Link
US (3) US8017627B2 (ja)
EP (3) EP1642578B2 (ja)
JP (2) JP4898073B2 (ja)
KR (2) KR100888275B1 (ja)
CN (2) CN100346788C (ja)
AT (1) ATE388705T1 (ja)
AU (2) AU2001281746C1 (ja)
CA (1) CA2417727C (ja)
CY (2) CY1107405T1 (ja)
DE (2) DE20122843U1 (ja)
DK (2) DK1642578T3 (ja)
EA (1) EA006384B1 (ja)
EE (1) EE05420B1 (ja)
ES (2) ES2302742T5 (ja)
HK (1) HK1089106A1 (ja)
IL (2) IL154041A0 (ja)
IS (1) IS2803B (ja)
NO (2) NO330565B1 (ja)
NZ (1) NZ524396A (ja)
PL (1) PL207845B1 (ja)
PT (2) PT1307194E (ja)
SI (2) SI1642578T2 (ja)
UA (2) UA77398C2 (ja)
WO (1) WO2002009707A1 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
NZ524396A (en) 2000-07-31 2003-09-26 Nycomed Danmark As Fentanyl composition for nasal administration comprising water as a solvent
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0305579D0 (en) * 2003-03-11 2003-04-16 Dallas Burston Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8865743B2 (en) * 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
NZ610790A (en) * 2006-04-13 2015-05-29 Nupathe Inc Transdermal methods and systems for the delivery of anti-migraine compounds
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
WO2009070829A1 (en) * 2007-12-05 2009-06-11 Krius Pty Ltd Non-aqueous oil-based fentanyl compositions for transmucosal administration
US8757146B2 (en) 2008-02-07 2014-06-24 University Of Washington Through Its Center For Commercialization Circumferential aerosol device
GB2464282A (en) * 2008-10-08 2010-04-14 Archimedes Dev Ltd A device for administering a dose of opioid analgesic
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
DE102009001041A1 (de) * 2009-02-20 2010-08-26 Marien-Apotheke Fulda Ohg Notfallset zur Herstellung eines Arzneimittels zur nasalen Anwendung von Opioiden bei Atemnot
WO2012024595A2 (en) 2010-08-20 2012-02-23 University Of Washington Circumferential aerosol device for delivering drugs to olfactory epithelium and brain
SI2670674T1 (sl) 2011-02-04 2016-11-30 Archimedes Development Limited Izboljšan vsebnik
RU2612506C2 (ru) 2011-03-03 2017-03-09 Импел Ньюрофарма Инк. Устройство для назальной доставки лекарственных средств
WO2012154859A1 (en) 2011-05-09 2012-11-15 Impel Neuropharma Inc. Nozzles for nasal drug delivery
BR112013029126A2 (pt) * 2011-05-13 2017-02-07 Euro Celtique Sa formas de dosagem farmacêuticas intranasais compreendendo naloxona
JP2016520378A (ja) 2013-04-28 2016-07-14 インペル ニューロファーマ インコーポレイテッド 医用単位用量コンテナ
MX2017008428A (es) 2014-12-23 2018-03-23 Acelrx Pharmaceuticals Inc Sistemas, dispositivos y métodos para dispensar formas de dosificación transmucosa oral.
US11266799B2 (en) 2015-09-10 2022-03-08 Impel Neuropharma, Inc. In-line nasal delivery device
EP3713628A4 (en) 2017-11-21 2021-08-18 Impel Neuropharma Inc. INTRA-NASAL DEVICE WITH DIVER TUBE
JP2021503988A (ja) 2017-11-21 2021-02-15 インペル ニューロファーマ インコーポレイテッド インレットインターフェースを用いた鼻腔内装置
EP3735244B1 (en) 2018-01-05 2022-11-23 Impel Pharmaceuticals Inc. Intranasal delivery of dihydroergotamine by precision olfactory device
EP3735223A4 (en) 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
WO2020018959A1 (en) 2018-07-19 2020-01-23 Impel Neuropharma, Inc. Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease
AU2019418744B2 (en) 2019-01-03 2023-08-03 Impel Pharmaceuticals Inc. Nasal drug delivery device
EP3969085A4 (en) 2019-05-17 2023-06-21 Impel Pharmaceuticals Inc. DISPOSABLE NASAL DELIVERY DEVICE
EP4230206A1 (en) 2020-10-15 2023-08-23 Pharmbiotest Poland SP.ZO.O. Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
FR2568773B1 (fr) * 1984-08-10 1989-03-03 Sandoz Lab Nouvelles compositions pharmaceutiques administrables par voie nasale
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
ZA875317B (en) * 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
US4916142A (en) * 1987-02-02 1990-04-10 Boc, Inc. N-heterocyclic-N-(4-piperidinyl)amides and pharmaceutical compositions and their use as analgesics
GB8900267D0 (en) † 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5019583A (en) * 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US5028616A (en) * 1989-09-05 1991-07-02 G. D. Searle & Co. N-benzylpiperidine amides
US5098915A (en) * 1989-09-05 1992-03-24 G. D. Searle & Co. Substituted N-benzylpiperidine amides
EP0532546B1 (en) * 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
AU5551394A (en) 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5466700A (en) * 1993-08-30 1995-11-14 Glaxo Wellcome Inc. Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
USRE38407E1 (en) * 1994-03-23 2004-01-27 Delex Therapeutics Inc. Pain management with liposome-encapsulated analgesic drugs
CA2189351C (en) * 1994-05-13 2008-12-30 Stephen J. Farr Narcotic containing aerosol formulation
US5958379A (en) * 1994-09-30 1999-09-28 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh Pharmaceutical composition
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
KR100453140B1 (ko) 1995-06-05 2005-02-28 앨자 코포레이션 펜타닐 및 수펜타닐의 경피 전기수송 전달을 위한 장치
IE960375A1 (en) 1995-06-05 1996-12-11 Alza Corp Device for transdermal electrotransport delivery of fentanyl¹and sufentanil
CA2224244C (en) * 1995-06-07 2007-03-20 O'neil, Christine Patient controlled drug delivery device
AUPN603895A0 (en) * 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US6608073B1 (en) * 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6660715B2 (en) * 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
WO2000047203A1 (en) † 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
US6680071B1 (en) * 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6677332B1 (en) * 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
CA2381860C (en) * 1999-08-26 2009-11-24 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
AU2001262992A1 (en) * 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US7049326B2 (en) * 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
WO2001092226A1 (en) * 2000-05-25 2001-12-06 Sepracor, Inc. Heterocyclic analgesic compounds and method of use thereof
WO2001097780A2 (en) 2000-06-22 2001-12-27 Pharmasol Ltd Pharmaceutical compositions comprising an opioid analgesic
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
NZ524396A (en) 2000-07-31 2003-09-26 Nycomed Danmark As Fentanyl composition for nasal administration comprising water as a solvent
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20020187996A1 (en) * 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
FR2829757B1 (fr) * 2001-09-20 2004-07-09 Commissariat Energie Atomique Procede de preparation d'un sol stable de zircono-titanate de plomb et procede de preparation de films a partir dudit sol
EP1535615A4 (en) * 2002-07-11 2010-03-31 Taiho Pharmaceutical Co Ltd COMPOSITION FOR THE NASAL ABSORPTION
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20060062812A1 (en) * 2003-03-11 2006-03-23 Calvin Ross Novel compositions
EA009881B1 (ru) * 2003-06-17 2008-04-28 Пфайзер Инк. Производные n-пирролидин-3-ил-амида в качестве ингибиторов обратного захвата серотонина и норадреналина
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
GB0514043D0 (en) 2005-07-08 2005-08-17 Arakis Ltd Fentanyl formulation
CA2637672C (en) * 2006-01-25 2012-07-24 Insys Therapeutics Inc. Sublingual fentanyl spray
WO2009047779A2 (en) 2007-06-20 2009-04-16 Nikki Nikhilesh Singh Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form
PT2180844T (pt) 2007-08-02 2018-04-06 Insys Dev Co Inc Nebulizador sub-lingual de fentanilo
WO2009070829A1 (en) 2007-12-05 2009-06-11 Krius Pty Ltd Non-aqueous oil-based fentanyl compositions for transmucosal administration

Similar Documents

Publication Publication Date Title
JP2008044951A5 (ja)
JP2004505052A5 (ja)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
JP2010132695A5 (ja)
EA201100313A1 (ru) Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
NZ604029A (en) Methods of treating bladder cancer
NZ585856A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
HK1139871A1 (en) Improvements in and relating to medicinal compositions
JP2010222367A5 (ja)
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
JP2009522376A5 (ja)
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
NZ585857A (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
JP2013541583A5 (ja)
JP2013536837A5 (ja)
JP2016505050A5 (ja)
RU2015134148A (ru) Галеновая форма для введения активного действующего вещества
JP2017531044A5 (ja)
CN105168119A (zh) 一种治疗鼻炎的复方滴鼻用凝胶制剂
ATE446309T1 (de) Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung